A Study to Assess the Pharmacokinetics of CC-122 in Subjects With Mild, Moderate, and Severe Renal Impairment

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 30, 2017

Primary Completion Date

December 23, 2017

Study Completion Date

December 23, 2017

Conditions

Renal Insufficiency

Interventions

DRUG

CC-122

All subjects will receive one 3 mg CC-122 capsule the morning of Day 1 which will be administered in the fasted state.

Trial Locations (2)

DaVita Clinical Research, Minneapolis

DaVita Clinical Research, Lakewood